Verve Therapeutics Inc (NASDAQ: VERV) kicked off on Tuesday, up 81.50% from the previous trading day, before settling in for the closing price of $6.27. Over the past 52 weeks, VERV has traded in a range of $2.86-$9.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -3.28%. With a float of $65.76 million, this company’s outstanding shares have now reached $88.80 million.
The firm has a total of 274 workers. Let’s measure their productivity. In terms of profitability, gross margin is 36.09%, operating margin of -349.68%, and the pretax margin is -303.09%.
Verve Therapeutics Inc (VERV) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verve Therapeutics Inc is 26.23%, while institutional ownership is 74.01%. The most recent insider transaction that took place on Apr 02 ’25, was worth 40,761. In this transaction Chief Executive Officer of this company sold 9,822 shares at a rate of $4.15, taking the stock ownership to the 346,686 shares. Before that another transaction happened on Apr 02 ’25, when Company’s Chief Administrative Officer sold 2,777 for $4.15, making the entire transaction worth $11,525. This insider now owns 17,420 shares in total.
Verve Therapeutics Inc (VERV) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -3.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.31% during the next five years compared to -42.43% drop over the previous five years of trading.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Take a look at Verve Therapeutics Inc’s (VERV) current performance indicators. Last quarter, stock had a quick ratio of 9.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.11, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.75 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Analysing the last 5-days average volume posted by the [Verve Therapeutics Inc, VERV], we can find that recorded value of 18.3 million was better than the volume posted last year of 3.34 million. As of the previous 9 days, the stock’s Stochastic %D was 84.27%. Additionally, its Average True Range was 0.83.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 99.77%, which indicates a significant increase from 99.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 236.89% in the past 14 days, which was higher than the 139.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.97, while its 200-day Moving Average is $5.74. Now, the first resistance to watch is $11.57. This is followed by the second major resistance level at $11.76. The third major resistance level sits at $12.12. If the price goes on to break the first support level at $11.02, it is likely to go to the next support level at $10.66. Now, if the price goes above the second support level, the third support stands at $10.47.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
The company with the Market Capitalisation of 1.01 billion has total of 89,143K Shares Outstanding. Its annual sales at the moment are 32,330 K in contrast with the sum of -198,710 K annual income. Company’s last quarter sales were recorded 32,980 K and last quarter income was -31,030 K.
